Key Takeaways
Linker chemistry is a primary determinant of antibody–drug conjugate (ADC) performance, governing systemic stability, payload release, and therapeutic index.
The balance between linker stability in circulation and efficient intracellular payload release defines the tradeoff between efficacy and toxicity in ADC design.
Cleavable and non-cleavable linkers drive distinct pharmacokinetic and intracellular processing pathways, influencing where and how payload activity occurs.
Linker–payload interactions, including hydrophobicity and release kinetics, directly impact aggregation, clearance, and overall developability.
Conjugation strategy and linker chemistry together control drug-to-antibody ratio (DAR) distribution, product heterogeneity, and manufacturing complexity, making them critical considerations for CDMOs and developers.
The Overlooked Control Point in ADC Design
Antibody–drug conjugates (ADCs) are typically described through two defining features: the specificity of the antibody and the potency of the cytotoxic payload. This framing reflects how the field has historically communicated their value: targeting plus killing. In practice, however, ADCs function as three-part systems in which the antibody, linker, and payload operate as an integrated whole. The linker is not simply a structural bridge between the other two components. It governs how and when the payload is delivered, and in doing so, it exerts a decisive influence over whether an ADC performs as intended in vivo.
At the most basic level, the linker regulates systemic stability. An ADC must circulate long enough to reach its target without prematurely releasing its payload into the bloodstream. If the linker is too labile, early release can increase systemic exposure to free drug, raising the risk of off-target toxicity. If it is too stable, the payload may not be released efficiently once the ADC is internalized into target cells, limiting therapeutic activity. This balance between stability in circulation and release at the site of action is not a secondary consideration; it is central to the pharmacological behavior of the molecule.
The linker also acts as the gatekeeper of payload release. It determines the mechanism by which the cytotoxic agent is liberated, whether through enzymatic cleavage, changes in pH, reductive conditions, or intracellular degradation processes. These release pathways shape not only the timing of drug activation but also its localization, influencing whether the payload remains confined to antigen-expressing cells or diffuses more broadly within the tumor microenvironment.
Thse roles position the linker as a primary determinant of therapeutic index. The same chemical features that stabilize an ADC in circulation must also enable efficient intracellular release, and the balance between these opposing requirements defines the window between efficacy and toxicity. While antibody selection and payload potency set the theoretical ceiling for performance, linker chemistry determines how much of that potential can be realized in practice.
This perspective reframes linker design from a supporting consideration to a central design logic. In ADC development, the linker is the mechanism through which biological targeting and chemical potency are translated into a clinically viable therapy.
Beyond Cleavable vs. Non-Cleavable
The most common way to categorize ADC linkers is by whether they are cleavable or non-cleavable. This distinction provides a useful starting point because it captures the fundamental difference in how payload release is triggered once the ADC reaches its target. Cleavable linkers are designed to respond to specific biochemical or environmental conditions, such as enzymatic activity, acidic pH, or reductive intracellular environments. These triggers enable the linker to release the payload in a controlled manner after internalization, or in some cases within the tumor microenvironment itself.1,2
Non-cleavable linkers follow a different pathway. Rather than responding to a discrete trigger, they rely on the intracellular degradation of the antibody component within lysosomal compartments. This process generates a payload-containing metabolite that retains part of the linker or amino acid residue from the antibody. As a result, the active species released inside the cell differs structurally from the free drug typically generated by cleavable systems, which can influence its permeability, potency, and intracellular distribution.1
These mechanistic differences have direct implications for pharmacokinetics and intracellular processing. Cleavable linkers introduce the possibility of payload release outside the target cell if the triggering conditions are present systemically or within the tumor microenvironment, which can affect both efficacy and safety. Non-cleavable linkers, by contrast, tend to exhibit greater stability in circulation because they do not respond to extracellular triggers, but their reliance on intracellular degradation means that payload activation is tightly coupled to efficient internalization and lysosomal processing.1,3
While this binary classification captures an important aspect of ADC behavior, it does not fully account for the range of outcomes observed in practice. Differences in trigger sensitivity, release kinetics, payload properties, and conjugation context can produce meaningful variation within each category. As a result, describing linkers as simply cleavable or non-cleavable is necessary for understanding their basic function, but it is not sufficient for predicting how a given ADC will perform in vivo.
Linkers as Regulators of Therapeutic Index
The central challenge in linker design lies in managing a fundamental tension between stability and release. An ADC must remain intact in circulation long enough to reach its target while also releasing its payload efficiently once internalized. These competing requirements define the therapeutic index, the window in which the drug can achieve efficacy without unacceptable toxicity. Linker chemistry sits at the center of this balance, shaping both sides of the equation.3,4
If a linker is insufficiently stable, payload release can occur before the ADC reaches its intended site of action. This premature release increases systemic exposure to the free cytotoxic agent, which can lead to off-target toxicity and reduce the amount of active drug delivered to tumor cells. In this scenario, the antibody’s targeting capability is effectively bypassed, and the ADC begins to behave more like a conventional chemotherapy agent.3,5
At the opposite extreme, a linker that is too stable may resist cleavage or degradation even after the ADC has been internalized. In this case, the payload remains conjugated and inactive, limiting its ability to exert cytotoxic effects within the target cell. The result is diminished efficacy despite adequate delivery of the ADC to the tumor. This highlights that stability alone is not a desirable endpoint; it must be paired with a release mechanism that functions reliably under intracellular conditions.3
Thus, therapeutic index is not determined solely by antibody specificity or payload potency. Instead, it emerges from how effectively linker design coordinates systemic stability with intracellular activation. Small changes in linker chemistry can shift this balance, altering both exposure and activity in ways that are not always predictable from the properties of the antibody or payload alone.4
Bystander Effect: Extending or Eroding Selectivity
Linker-mediated payload release does not always confine cytotoxic activity to antigen-expressing cells. In some cases, the released drug can diffuse across cell membranes and affect neighboring cells, a phenomenon commonly referred to as the bystander effect. This mechanism depends on both the release characteristics of the linker and the physicochemical properties of the payload, particularly its ability to cross cellular membranes after liberation.6
When an ADC releases a membrane-permeable payload, the drug can move beyond the initially targeted cell and enter adjacent cells within the tumor microenvironment. This can be advantageous in tumors where antigen expression is heterogeneous, allowing the ADC to eliminate cells that may not express sufficient levels of the target antigen to support direct binding and internalization. In this context, linker design and payload selection work together to extend the functional reach of the therapy beyond the cells that the antibody alone can engage.
At the same time, this expanded activity introduces a tradeoff. The same properties that enable diffusion into neighboring tumor cells can also allow the payload to affect healthy tissues if release occurs outside the intended target or if the drug circulates systemically after cleavage. As a result, the bystander effect can erode the selectivity that ADCs are designed to achieve, increasing the risk of off-target toxicity. The extent of this effect depends on multiple factors, including where and how the payload is released, as well as the permeability and stability of the released species.
Linker design does more than control whether a payload is released; it shapes the spatial distribution of drug activity after release. In doing so, it influences whether an ADC behaves as a strictly targeted therapy or as a more diffusely acting agent within the tumor and potentially beyond.
The Linker–Payload System
Linker performance cannot be evaluated in isolation from the payload it carries. Together, the linker and payload form a functional unit whose combined properties determine how an ADC behaves in circulation, during internalization, and after drug release. Among the most influential of these shared properties are hydrophobicity, release kinetics, and stability, each of which emerges from the interaction between linker chemistry and payload structure.3,7
Hydrophobicity provides a clear example of this interdependence. Many cytotoxic payloads used in ADCs are inherently hydrophobic, and when combined with certain linker designs, this can increase the overall hydrophobic character of the conjugate. Elevated hydrophobicity has been associated with a greater tendency toward aggregation, which can in turn affect stability, pharmacokinetics, and clearance. These effects are not dictated by the payload or linker alone but by how the two contribute to the physicochemical profile of the conjugated molecule.7,8
Release kinetics are similarly shaped by the combined system. The rate and efficiency with which a payload is liberated depend on both the trigger sensitivity of the linker and the chemical nature of the bond connecting it to the drug. At the same time, the properties of the released payload, such as its solubility and membrane permeability, determine how it behaves after cleavage. A linker that releases a payload efficiently is only effective if the released species can access its intracellular target and retain its activity.3
Stability must also be considered in this integrated context. Linker modifications intended to improve plasma stability may alter the way the payload is presented or released, while payload-driven adjustments to improve potency or permeability can introduce new stability challenges. These tradeoffs highlight that optimizing one parameter in isolation can shift the balance of the overall system in unintended ways.7
For these reasons, linker selection cannot be approached as a standalone decision. It must be aligned with the properties and requirements of the payload from the outset. The performance of an ADC depends on how effectively the linker–payload system is tuned to achieve the desired balance of stability, release, and activity within a complex biological environment.
Conjugation and Linker Chemistry: Controlling Heterogeneity
While linker design governs stability and release, the way the linker–payload is attached to the antibody introduces another layer of control and variability. Conjugation strategy determines how many payload molecules are attached, where they are located on the antibody, and how consistent those attributes are across a batch. In this context, linker chemistry and conjugation approach function together as key drivers of heterogeneity in ADCs.7,9
Traditional, or stochastic, conjugation methods typically target naturally occurring amino acid residues such as lysines or cysteines. Because these residues are distributed across the antibody surface, the resulting ADC population contains a mixture of species with different drug-to-antibody ratios (DARs) and attachment sites. This heterogeneity can influence pharmacokinetics, as species with higher DARs often exhibit altered stability, increased hydrophobicity, and faster clearance relative to lower-DAR counterparts. As a result, the overall behavior of the ADC reflects a weighted average of multiple molecular variants rather than a single defined entity.7,10
Site-specific and site-selective conjugation strategies have been developed to address this variability by directing linker attachment to defined locations on the antibody. These approaches can produce more homogeneous ADC populations with narrower DAR distributions, which in turn can reduce pharmacokinetic variability and improve the predictability of in vivo performance. However, achieving this level of control introduces additional considerations, including the need for engineered antibodies, specialized conjugation chemistries, and more complex process development workflows.9
From an analytical and manufacturing perspective, these differences are significant. Heterogeneous ADC mixtures require more extensive characterization to define DAR distribution, structural variants, and stability profiles. As conjugation strategies become more precise, analytical expectations often shift toward tighter control and deeper understanding of product attributes. Linker chemistry plays a role in both cases, influencing not only how payloads are attached but also how different species behave during purification, storage, and use.7,9
For development and manufacturing partners, controlling heterogeneity is not simply a matter of improving product consistency. It is a means of aligning molecular design with pharmacokinetic behavior and clinical performance. Conjugation strategy and linker chemistry together determine whether an ADC can be produced reproducibly and whether its behavior can be predicted with confidence across development stages.
Aggregation, Hydrophobicity, and Developability
Among the many variables that influence ADC performance, hydrophobicity stands out as one of the most immediate and practical constraints on development. The combination of a hydrophobic payload with certain linker chemistries can increase the overall hydrophobic character of the conjugate, which in turn affects how the molecule behaves during manufacturing, formulation, and in vivo circulation. Rather than just abstract design considerations, these effects directly shape whether an ADC can be produced, stabilized, and delivered as a viable therapeutic.7,8
Increased hydrophobicity is closely associated with aggregation propensity. As the linker–payload contribution to hydrophobic surface area rises, ADC molecules are more likely to self-associate, particularly at higher DARs. Aggregation can complicate purification processes, reduce yield, and create challenges in maintaining product consistency. It also introduces risks during storage, where aggregated species may accumulate over time, affecting shelf life and stability.7
These properties carry through into formulation. Highly hydrophobic ADCs may require more complex formulation strategies to maintain solubility and prevent aggregation under clinically relevant conditions. Buffer composition, excipient selection, and concentration limits all become more constrained as hydrophobicity increases. In some cases, linker modifications that introduce hydrophilic elements are used to offset these effects, illustrating again that linker design is a central lever for managing developability.8
Hydrophobicity and aggregation also influence pharmacokinetics, particularly clearance. ADC species with higher hydrophobicity or aggregation tendency have been associated with faster systemic clearance, which can reduce effective exposure and limit therapeutic activity. This creates a feedback loop in which design choices intended to increase potency, such as higher payload loading, introduce developability challenges that ultimately compromise performance.7,11
For developers and manufacturing partners, these constraints are often among the first to surface and the hardest to resolve late in development. Unlike target biology or payload mechanism, which may be adjusted through molecule selection, hydrophobicity-driven issues are embedded in the physicochemical profile of the ADC. As a result, aggregation and developability considerations must be addressed early, with linker chemistry playing a central role in shaping a molecule that is not only effective but also manufacturable and stable.
Platform Strategies vs. Molecule-Specific Optimization
As ADC development has matured, there has been increasing interest in platform approaches to linker chemistry and conjugation. These strategies aim to standardize key elements of design and manufacturing, enabling greater consistency across programs. Platform linker systems and conjugation technologies can support more predictable DAR control, improved batch-to-batch reproducibility, and streamlined process development. In a manufacturing context, this consistency can translate into more efficient scale-up and reduced variability, which are critical for advancing molecules through clinical and commercial stages.9
Scalability is a central driver of this interest. Platform approaches allow development teams to build on established chemistries and processes rather than starting from first principles for each new molecule. This can shorten development timelines, simplify technology transfer, and reduce the burden on analytical and process development teams. For contract development and manufacturing organizations (CDMOs) in particular, platform capabilities can provide a foundation for repeatable execution across multiple client programs while maintaining control over key quality attributes.9
At the same time, ADCs resist full standardization. The performance of any given molecule depends on a tightly interrelated set of factors, including the antibody target, internalization behavior, payload properties, linker chemistry, conjugation site, and desired DAR. Even when a platform linker or conjugation method is used, these variables can shift the balance of stability, release, and pharmacokinetics in ways that require molecule-specific optimization. As a result, platform strategies can provide a starting point, but they do not eliminate the need for tailored design decisions.7
This creates an inherent tension in ADC development. On one side is the drive toward platformization, with its advantages in consistency, scalability, and operational efficiency. On the other is the reality that each ADC represents a unique integration of biological and chemical components that must be tuned to achieve the desired therapeutic profile. Effective development strategies recognize both forces, using platform tools where they add value while preserving the flexibility to adapt linker and conjugation choices to the specific requirements of each molecule.
Implications for Development and Manufacturing Partners
Decisions about linker chemistry are often made early in discovery, but their consequences extend across the entire development life cycle. Choices that affect stability, release kinetics, hydrophobicity, and conjugation strategy ultimately shape how an ADC can be analyzed, formulated, and manufactured at scale. What begins as a molecular design decision becomes a defining factor in downstream feasibility and risk.
Analytical requirements provide a clear example of this propagation. Linker chemistry influences not only drug-to-antibody ratio distribution but also the formation of variants, degradation products, and payload-related species that must be characterized and controlled. More heterogeneous systems require broader analytical methods to define product composition and stability, while more homogeneous systems often demand tighter specifications and deeper characterization. In both cases, the analytical burden reflects upstream design choices rather than being imposed independently at later stages.9
Formulation challenges follow a similar pattern. As discussed earlier, linker–payload combinations can drive hydrophobicity and aggregation risk, which in turn affect solubility, stability, and storage conditions. These properties constrain formulation strategies and may necessitate specific excipients or concentration limits to maintain product quality. Adjustments at this stage are often reactive, addressing characteristics that were built into the molecule earlier in development.7
Scale-up further amplifies these effects. Conjugation efficiency, purification behavior, and product consistency are all influenced by linker chemistry and conjugation approach. Processes that perform adequately at small scale may encounter challenges when translated to larger volumes, particularly if heterogeneity or instability complicates control of critical quality attributes. As a result, linker-related decisions can determine not only whether an ADC can be manufactured reproducibly but also how efficiently that manufacturing can be executed.9
These interdependencies position development and manufacturing partners, particularly CDMOs, as integrators across disciplines. Effective support requires the ability to connect chemical design with biological function and process performance, anticipating how early decisions will influence later stages. Rather than treating linker chemistry as an isolated element of molecular design, successful development programs incorporate it into a coordinated strategy that spans analytics, formulation, and manufacturing from the outset.
Conclusion: The Linker as Design Logic
Across each stage of ADC development, the same pattern emerges: linker chemistry determines how the promise of targeted delivery and potent cytotoxicity is realized in practice. It governs whether the molecule remains stable in circulation, whether and how the payload is released, how far that payload can act once liberated, and how the resulting conjugate behaves during manufacturing and formulation.
Antibody selection defines where an ADC can go, and payload choice defines what it can do. The linker defines whether those capabilities can be translated into consistent, controllable performance in a biological system. It sets the conditions under which efficacy can be achieved without unacceptable toxicity, and it determines whether the molecule can be produced, characterized, and scaled in a reproducible way. In this sense, linker chemistry is not a supporting element of ADC design but the mechanism through which its core components are coordinated.
For developers and manufacturing partners alike, this reframes how ADCs should be approached. Linker decisions are not problems to solve after target and payload have been selected. They are central design choices that shape the therapeutic index, the developability profile, and the operational feasibility of the program from the outset. Recognizing this shifts linker chemistry from a technical detail to a guiding principle.
Linker chemistry is the primary control point through which ADC developers translate biological targeting and payload potency into a clinically viable and manufacturable therapy.
References
1. Lu, Jun, et al. “Linkers Having a Crucial Role in Antibody–Drug Conjugates.” Int. J. Mol. Sci. 17: 561 (2016).
2. Su, Zheng, et al. “Antibody–drug conjugates: Recent advances in linker chemistry.” Acta Pharm. Sin. B. 11: 3889–3907 (2021).
3. Su, Sian and Donglu Zhang. “Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency.” Front. Pharmacol. Sec. Translational Pharmacology. 12: 687926 (2021).
4. Tang, Shou-Ching, et al. “Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis.” Cancer and Metastasis Reviews. 44: 18 (2025).
5. Nguyen, Toan D, Brandon M Bordeau, and Joseph P Balthasar. “Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.” Cancers (Basel). 15: 713 (2023).
6. Wang, Yiming, et al. “Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity.” Critical Reviews in Oncology/Hematology. 216: 104979 (2025).
7. Mills, Brittney J, et al. “Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs.” Journal of Pharmaceutical Sciences. 109: 1662–1672 (2020).
8. Evers, Andreas, et al. “Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET.” MAbs. 16: 2302386 (2024).
9. Fan, Qirui, et al. “A review of conjugation technologies for antibody drug conjugates.” Antib. Ther. 8: 157–170 (2025).
10. Donaghy, Heather. “Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.” MAbs. 8: 659–671 (2016).
11. Mckertish, Candice Maria, and Veysel Kayser. “Advances and Limitations of Antibody Drug Conjugates for Cancer.” Biomedicines. 9: 872 (2021).
